JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present) [0.03%]
Janus激酶3抑制剂在炎症和自身免疫性疾病治疗中的应用：专利回顾（2016-至今）
Chengjuan Chen,Dianxiang Lu,Tao Sun et al.
Chengjuan Chen et al.
Introduction: Up to now, a total of eight Janus kinase (JAK) inhibitors have been approved for the treatment of autoimmune and myeloproliferative disease. The JAK family belongs to the non-receptor tyrosine kinase family,...
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021) [0.03%]
海洋天然产物作为新药来源的专利回顾(2018年7月-2021年7月)
Paromita Banerjee,Anita Mandhare,Vrushali Bagalkote
Paromita Banerjee
Introduction: Marine natural products have aided as rich sources of new bioactive agents. The multiplicity of marine habitations and exclusive ecological conditions of the sea offer mostly unexploited sources of unique bi...
An updated patent review on drugs for the treatment of tuberculosis (2018-present) [0.03%]
治疗结核病药物的专利综述更新（2018年至今）
Sarfaraz Ahmed,Sisir Nandi,Anil K Saxena
Sarfaraz Ahmed
Introduction: Tuberculosis (TB) caused by Mycobacterium tuberculosis (M.tb) has been a global challenge as 1.4 million deaths were reported in 2019, which included deaths attributed to HIV-TB co-infection. It is curable b...
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present) [0.03%]
小分子c-Met激酶抑制剂的专利综述（2018年至今）
Cilong Chu,Zixuan Rao,Qingshan Pan et al.
Cilong Chu et al.
Introduction: c-Met tyrosine kinase receptor is a high-affinity ligand of hepatocyte growth factor (HGF). c-Met is widely expressed in a variety of normal human tissues, but shows abnormally high expression, amplification...
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present) [0.03%]
选择性雌激素受体降解物(SERD)和共价拮抗剂(SERCAs)：专利回顾(2015年至今)
James S Scott,Bernard Barlaam
James S Scott
Introduction: The estrogen receptor (ER) is a clinically validated oncology target with a pivotal role in hormonally driven breast cancer, the most prevalent form of female cancer. Current treatments that directly modulat...
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 2013 [0.03%]
专利文献中自2013年以来USP30抑制剂作为去泛素酶的有趣作用
Sofia Ferrer,Michael E Muratore,Peter Buijnsters
Sofia Ferrer
Introduction: Ubiquitin specific peptidase 30 (USP30) is a mitochondrial deubiquitinase that antagonizes ubiquitination-mediated mitophagy of damaged or impaired mitochondria driven by the activity of PARK2/Parkin ubiquit...
Alexander Kazantsev,Mikhail Krasavin
Alexander Kazantsev
Introduction: Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase has been extensively studied due to its involvement in many biological processes. It has also been identified as the target for imm...
Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property [0.03%]
调节血红蛋白变构来治疗镰状细胞病：目前的进展和知识产权
Piyusha P Pagare,Aref Rastegar,Osheiza Abdulmalik et al.
Piyusha P Pagare et al.
Introduction: Sickle cell disease (SCD) is a debilitating inherited disorder that affects millions worldwide. Four novel SCD therapeutics have been approved, including the hemoglobin (Hb) modulator Voxelotor. ...
TGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present) [0.03%]
TGR5激动剂在糖尿病治疗中的应用：专利回顾及临床进展（2012年至今）
Rachana S Bhimanwar,Amit Mittal
Rachana S Bhimanwar
Introduction: A cell surface bile acid receptor TGR5 is expressed in various tissues, including the liver, kidney, intestine, and adrenal glands, causing its effect in each tissue to differ. A major role for TGR5 is to ma...